Navigation Links
EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations

EXTON, Penn., Feb. 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' report, ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, which contains data from 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts:

  • On average, nephrologists in the EU5 countries indicate that they are managing slightly over 100 dialysis patients and over 200 Stage 3 and 4 CKD-ND patients
  • In all countries, the general practitioner is the most common referral source to the nephrologist, accounting for 40-60 percent of all nephrology patient referrals
  • Phosphate binder treatment prevalence in both the dialysis and CKD-ND has remained consistent over time
  • Approximately 73 percent of nephrologists report that they initiate binders when dialysis patients are above the phosphorus level at which the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend, clearly indicating that more education is needed
  • As is the case in the United States market, calcium and non-calcium binders generally split the phosphate binder market. However, Fosrenol (Shire) use is higher in the EU5 compared to the U.S. and as well, use of sevelamer's (Sanofi Renal) powder formulation is higher in the EU5 compared to the U.S.
  • Prevalence of Nutritional Vitamin D treatment in dialysis patients appears to be increasing across both dialysis modalities, with currently over 30 percent of dialysis patients treated in 2012
  • Physicians' choice of Active Vitamin D varies by EU5 country, with U.K. and French physicians choosing alfacalcidol most often in both their dialysis and CKD-ND patients, German and Italian physicians choosing calcitriol most often and Spanish physicians choosing paricalcitol (Abbott's Zemplar) most often
  • Mimpara (Amgen) use in the EU5 countries has remained consistent over time
  • (Logo:

    "While phosphate binder treatment prevalence has remained consistent from the prior year, we are now seeing patient share changes with regards to the brands and formulations, especially as it relates to sevelamer and Fosrenol," said Rob Dubman , BioTrends' Director of Nephrology.

    ChartTrends®: Bone and Mineral Metabolism in Dialysis and CKD-ND (EU5) is a syndicated report series, in which 210 nephrologists provided patient chart data on 962 dialysis patients in the EU5 and 191 nephrologists provided patient chart data on 928 CKD-ND patients in the EU5 in the most recent wave of research to uncover the actual management related to bone and mineral metabolism. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

    The study also evaluated referral patterns, co-morbidities, blood transfusions, hospitalizations and a host of other patient demographics and laboratory data. BioTrends is publishing ChartTrends: Bone and Mineral Metabolism in dialysis later this year in the US. Additional ChartTrends reports have been published in China and Latin America (Brazil, Argentina and Mexico).

    About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or

    About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

    All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research GroupDecision Resources GroupRob Dubman

    Christopher Comfort781-993-2592


    SOURCE BioTrends Research Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical to Report Fourth Quarter 2012 Results Release and Host Conference Call on February 19, 2013
    2. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
    3. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
    4. InspireMD Reports Results for Period Ended Dec. 31, 2012
    5. Sequenom CMMs MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities
    6. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at
    7. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
    8. Monoclonal Antibody Industry 2013 Global and China Market Analysis in New Research Report at
    9. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
    10. Wound and Tissue Management Market in Brazil: Abridged Competitive Analysis, Partial Numerical Data, CAGRs And Qualitative Synopses in New Research Report at
    11. Abaxis Reports Record Revenues For The Third Quarter Of Fiscal 2013
    Post Your Comments:
    (Date:10/12/2015)... Okla. , Oct. 12, 2015  Millions of ... free from the shackles of tobacco. An April ... at Kings College London showed electronic cigarettes to be ... smoking. But more than a decade after the technology ... it remained unchanged.    --> ...
    (Date:10/12/2015)... , Oct. 12, 2015 ... improve and enhance the quality of images produced ... substances (contrast media) used in magnetic resonance imaging, ... These devices allow the radiologists to interpret the ... conditions of the body. Contrast media can be ...
    (Date:10/12/2015)... -- In a Sutter Institute of Medical Research study published ... Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was ... patients in the early, pre-dementia phase of Alzheimer,s disease. ... extracted from the plasma of more than 1,000 blood ... found in patients with Alzheimer,s disease. Sutter Institute of ...
    Breaking Medicine Technology:
    (Date:10/12/2015)... ... October 12, 2015 , ... ... 19, 2015, high school aged female athletes, particularly in the area of track ... motion and mechanical overuse injuries than male peers in the same age group. ...
    (Date:10/12/2015)... AL (PRWEB) , ... October 12, 2015 , ... American ... continues to expand its footprint by opening its 151st medical center. Located at 606A ... , “We’re excited to continue fulfilling our mission of making quality health care ...
    (Date:10/12/2015)... ... October 12, 2015 , ... Advera Health Analytics, Inc . is ... Managed Care Organizations (MCOs) in order to provide health plans, payers, systems, and hospitals ... process. In addition, the DSM is also being offered to healthcare media organizations to ...
    (Date:10/12/2015)... ... October 12, 2015 , ... SQM Group is proud ... contact channel benchmarking study. Be a part of this insightful and leading-edge ... customer experience, customer journey, contact channel execution and intelligence, workforce optimization, and tools ...
    (Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... For the ... year earning the highest distinction with its first Platinum Award. , The Bizrate ... status, but also earned a score of at least 9.0 or above out of ...
    Breaking Medicine News(10 mins):